A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Osteoarthritis

Treatments: Drug: Comparator: celecoxib, placebo; Drug: MK0966, rofecoxib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092352

2004_070

0966-219

Details and patient eligibility

About

The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.

Full description

The duration of treatment is 6 weeks.

Enrollment: 395 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Osteoarthritis of the knee which requires treatment with medication for pain relief

Exclusion criteria

• Any known allergy to the study drug

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind